Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Nov 3, 2021
-
Oct 12, 2021-- Interim results from the Phase 1 study show a favorable safety and tolerability profile with no drug-related severe or serious adverse events at doses up to and including 120 mg/kg single dose and 80mg/kg multi-dose administered intravenously, or IV.
-
Oct 11, 2021- Event to be webcast live on Tuesday, October 12, 2021, at 5:30 a.m. PT -